BIO-Europe® 2016: AdAlta CEO on shark antibody technology

December 6, 2016
AdAlta is developing a novel technology platform that engineers the key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease. Sam Cobb, managing director and CEO of the Australian biotech, talks to Scrip senior writer Lucie Ellis about the company’s recent public listing and clinical development plans for lead product, AD-114, in idiopathic pulmonary fibrosis.
Previous Video
BIO-Europe® 2016: Opportunities For unpartnered assets
BIO-Europe® 2016: Opportunities For unpartnered assets

Steven Muntner, vice president of deals at Informa Pharma Intelligence, discusses key takeaways from a rece...

Next Video
BIO-Europe® 2016: Promethera extends series C on interest from Asian investors
BIO-Europe® 2016: Promethera extends series C on interest from Asian investors

Dr. John Tchelingerian, CEO of Promethera Biosciences, talks to Scrip senior writer Lucie Ellis on the side...